Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Clin Med Insights Oncol. 2011;5:171-6. doi: 10.4137/CMO.S6643. Epub 2011 May 29.
Gemcitabine is a chemotherapeutic agent used for the treatment of a number of malignancies. Although its major dose-limiting side effect is myelosuppression, many pulmonary toxicities have been described with its use. Severe pulmonary toxicity is rare, but symptoms tend to be rapid in onset and potentially deadly. The average time from initiation of chemotherapy to onset of symptoms is less than two months. The most effective therapy is steroid administration, the efficacy of which has been variable. In this report, we describe a unique case of gemcitabine pulmonary toxicity in a patient who did not experience symptoms of pulmonary dysfunction until after 1 year of treatment. Her symptoms did not improve rapidly with steroids, nor did she rapidly decompensate as has been frequently described. To our knowledge, this is one of the first reported descriptions of late-onset gemcitabine lung toxicity.
吉西他滨是一种用于治疗多种恶性肿瘤的化疗药物。尽管其主要的剂量限制副作用是骨髓抑制，但在使用过程中已经描述了许多肺部毒性。严重的肺部毒性很少见，但症状往往迅速出现，并有潜在的致命性。从开始化疗到出现症状的平均时间不到两个月。最有效的治疗方法是使用类固醇，其疗效各不相同。在本报告中，我们描述了一例吉西他滨肺毒性的独特病例，该患者在治疗 1 年后才出现肺部功能障碍的症状。她的症状没有像经常描述的那样迅速用类固醇改善，也没有迅速恶化。据我们所知，这是首例报道的吉西他滨肺毒性迟发性病例之一。
